{"product_id":"lsta-swot-analysis","title":"(LSTA) Lisata Therapeutics, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Reference Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Lisata Therapeutics, Inc. SWOT Analysis summarizes the company’s core strengths, weaknesses, market opportunities, and external threats—useful for investment, strategy, or research—and this page includes a real preview\/sample of the analysis so you can see the format and depth before buying. Purchase the full version to receive the complete ready-to-use SWOT report. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 clinical programs in Phase II\/IIb\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics has 3 mid-stage clinical programs, HONEDRA, XOWNA, and CLBS201, across Phase II\/IIb. They target critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease, so one pipeline can drive several readouts. That mix gives Lisata more than one shot at value creation as each program reaches data milestones.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHONEDRA with SAKIGAKE designation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHONEDRA’s SAKIGAKE designation in Japan gives Lisata Therapeutics, Inc. a clear regulatory edge, since the program is meant to speed priority development and review for promising therapies. That can lift the asset’s visibility with regulators and partners, while signaling strong innovation potential. In a market where faster review can matter, this status can improve the program’s strategic profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocused on vascular and renal diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. is focused on vascular and renal diseases, including critical limb ischemia, coronary microvascular dysfunction, and chronic kidney disease. That targets large unmet needs: chronic kidney disease affects about 37 million U.S. adults, and critical limb ischemia carries high amputation and death risk. A tight disease focus can sharpen trial design, payer messaging, and commercial execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFounded in 1980\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLisata Therapeutics was founded in 1980, giving it about 46 years of operating history in 2026. That long run can support deeper institutional knowledge, steadier development processes, and better recall of what works across biotech cycles. It also signals durability, since the Company has stayed active through multiple funding, regulatory, and market shifts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFounded in 1980\u003c\/li\u003e\n\u003cli\u003eAbout 46 years of history\u003c\/li\u003e\n\u003cli\u003eSupports continuity and know-how\u003c\/li\u003e\n\u003cli\u003eShows survival across industry cycles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCD34+ cell therapy and tissue-repair platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc.'s CD34+ cell-therapy platform is a real strength because it targets tissue repair and disease reversal, not just symptom control. CLBS201 adds depth beyond a single asset, showing the platform can support more than one program. In regenerative medicine, that kind of differentiated biology can create more durable value than a one-drug story.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets repair, not just symptoms\u003c\/li\u003e\n\u003cli\u003eCLBS201 broadens platform depth\u003c\/li\u003e\n\u003cli\u003eStands out in regenerative medicine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLisata’s 3-Asset Pipeline and Japan Edge Support a Differentiated Growth Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. has 3 mid-stage assets in Phase II\/IIb, giving it multiple near-term readouts and reducing single-asset risk. HONEDRA also has SAKIGAKE status in Japan, a regulatory edge that can speed review. Its CD34+ platform and focus on vascular and renal disease support a differentiated story.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline depth\u003c\/td\u003e\n\u003ctd\u003e3 Phase II\/IIb programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory edge\u003c\/td\u003e\n\u003ctd\u003eHONEDRA SAKIGAKE\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003eCD34+ cell therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Lisata Therapeutics, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Lisata Therapeutics, Inc. SWOT snapshot to reduce research friction and speed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources (trials, SEC filings, peer‑reviewed studies) to speed due diligence and verify Lisata Therapeutics’ market, pricing, and competitive claims.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo approved commercial products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics remains a clinical-stage biopharmaceutical company, so it still has no approved commercial product or product sales. That leaves 2025-2026 results tied to collaboration and grant income, while R\u0026amp;D spending and trial outcomes drive performance. Until an FDA-approved product reaches market, cash burn and dilution risk stay tied to clinical and regulatory progress.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAll lead assets remain in Phase II\/IIb\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. still has no lead asset in late-stage testing: HONEDRA is in Phase II, XOWNA is in Phase IIb, and CLBS201 remains in development. That leaves the pipeline exposed to high trial failure risk and long approval timelines. Without Phase III data, near-term revenue visibility stays weak and financing pressure can rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnly 3 named clinical candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. has only 3 named clinical candidates, so the pipeline is highly concentrated. That means each trial result carries outsized impact on valuation and cash use, while one setback can weaken the whole story. With only 3 programs, near-term diversification is limited, and the company has less room to offset delays or clinical misses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh dependence on trial milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. is still a clinical-stage company, so its case rests on trial enrollment, endpoint success, and clean readouts. If a study slips by even one quarter, the whole timeline can move, because valuation is tied to the next data point rather than current sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial delays can slow value creation\u003c\/li\u003e\n\u003cli\u003eEndpoint misses can reset the thesis\u003c\/li\u003e\n\u003cli\u003eRegulatory timing adds execution risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes milestone execution the main weakness: fewer buffers, higher sensitivity to data timing, and more downside if patient recruitment or regulatory review lags.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple name changes since 1980\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. has changed names several times since 1980, from NeoStem, Inc. to Caladrius Biosciences, Inc., then to Lisata Therapeutics, Inc. in 2022. That kind of rebranding can weaken market recall and make the Company harder to track across older filings, news, and investor materials. It can also lengthen the time needed for long-term shareholders to connect the current story with the prior identity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNeoStem, Inc. to Caladrius Biosciences, Inc.\u003c\/li\u003e\n\u003cli\u003eRenamed Lisata Therapeutics, Inc. in 2022\u003c\/li\u003e\n\u003cli\u003eCan dilute brand recognition\u003c\/li\u003e\n\u003cli\u003eCan disrupt investor memory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLisata's revenue gap and pipeline risk stay high\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. remains weak on revenue because it is still clinical stage and has no approved product sales. Its 3 named candidates are concentrated in Phase II to Phase IIb, so one trial miss can hit valuation hard. Cash burn and dilution risk stay high until a late-stage readout or approval improves funding visibility. Rebranding since 2022 can also limit investor recall.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo sales\u003c\/td\u003e\n\u003ctd\u003eClinical-stage only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline depth\u003c\/td\u003e\n\u003ctd\u003e3 named candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStage risk\u003c\/td\u003e\n\u003ctd\u003ePhase II to IIb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand history\u003c\/td\u003e\n\u003ctd\u003eRenamed in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eLisata Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; buy now to unlock the complete, editable version covering Lisata Therapeutics' strengths, weaknesses, opportunities, and threats in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHONEDRA Japan development pathway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHONEDRA’s SAKIGAKE designation in Japan can speed review and raise its profile with regulators, which matters in a market of about 123 million people. Under Japan’s SAKIGAKE pathway, review can be shortened to roughly 6 months in some cases, improving the odds of an earlier launch. If Lisata Therapeutics, Inc. wins a strong outcome, Japan could become a major regional commercial base for HONEDRA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXOWNA Phase IIb data in coronary microvascular dysfunction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXOWNA’s Phase IIb readout in coronary microvascular dysfunction could be a key de-risking event for Lisata Therapeutics, Inc. Positive data would push the program closer to late-stage development and raise its odds of becoming a larger cardiovascular asset. It would also widen Lisata Therapeutics, Inc.’s reach beyond its core focus and give investors a clearer shot at a new heart-disease market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLBS201 in chronic kidney disease not on dialysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCLBS201 in chronic kidney disease not on dialysis could address a large unmet need: the CDC says 1 in 7 U.S. adults has CKD, and most are not yet on dialysis. That patient pool is far bigger than the dialysis segment, so even modest clinical success could expand Lisata Therapeutics, Inc.'s renal franchise. If efficacy holds, the program could open a broader commercial path in a high-burden market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnerships with larger biopharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc.’s early-stage pipeline still leaves room for a larger biopharma partner to fund late-stage work, add development know-how, and widen access across regions. That can also lower the cash burn and execution risk tied to going solo. For a small biotech, a partner can turn one lead asset into a broader commercial path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFunding for later trials\u003c\/li\u003e\n\u003cli\u003eBetter regulatory and launch support\u003c\/li\u003e\n\u003cli\u003eLower solo-development burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpansion into regenerative medicine indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc.'s platform is built to repair damaged tissue and slow disease progression, so it can fit more than one indication. Its lead asset, certepetide (CEND-1), is already being tested across cancer and tissue-injury settings, which supports extension into new regenerative medicine uses. Each added indication can widen the addressable market and spread development risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatform may fit multiple disease areas.\u003c\/li\u003e\n\u003cli\u003eMore indications can expand market size.\u003c\/li\u003e\n\u003cli\u003eSame mechanism can support pipeline reuse.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLisata’s Japan Fast Track Could Unlock a Faster, Broader Growth Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHONEDRA’s SAKIGAKE path in Japan could shorten review to about 6 months, giving Lisata Therapeutics, Inc. a faster route into a 123 million-person market. XOWNA’s Phase IIb readout in coronary microvascular dysfunction is a key catalyst that could de-risk the pipeline and broaden Lisata Therapeutics, Inc. beyond oncology. CLBS201 also targets a large CKD pool, since 1 in 7 U.S. adults has chronic kidney disease.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHONEDRA Japan\u003c\/td\u003e\n\u003ctd\u003e~6-month review; 123M market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXOWNA\u003c\/td\u003e\n\u003ctd\u003ePhase IIb catalyst\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCLBS201\u003c\/td\u003e\n\u003ctd\u003e1 in 7 U.S. adults with CKD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase II and Phase IIb clinical failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc.'s core value still depends on certepetide in Phase II\/IIb, so the risk of missing a primary endpoint is real. Mid-stage oncology trials often enroll only dozens to low hundreds of patients, which makes efficacy noise and safety signals harder to dismiss. One setback at this stage can cut the stock fast because there is no late-stage data buffer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory uncertainty across programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEven with SAKIGAKE designation, Lisata Therapeutics, Inc. still must prove safety, efficacy, and CMC (chemistry, manufacturing, and controls) for each asset. PMDA and FDA reviews can add 6-12 months or more if data gaps appear, lifting trial and filing costs. With only one lead asset, certepetide, any delay can hit the whole pipeline and stretch cash use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompetition in vascular and renal therapeutics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. faces crowded vascular and renal fields where established drugs already generate multi-billion-dollar sales and newer cell-therapy programs are advancing fast. Larger biopharma firms can outspend on trials, manufacturing, and sales, while more than a dozen renal and vascular programs can chase the same patients. That competition can weaken Lisata Therapeutics, Inc.'s partnering leverage and limit share gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital needs of a clinical-stage biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. faces a heavy capital load because clinical-stage biotech firms must keep funding trials before any product sales start. Phase 2 and Phase 3 studies can cost millions of dollars, so Lisata may need more equity, debt, or partnership cash to keep programs moving. That raises dilution risk and can strain the balance sheet if financing terms turn weak.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOngoing trial spend needs fresh capital\u003c\/li\u003e\n\u003cli\u003eNo approved product means no product cash\u003c\/li\u003e\n\u003cli\u003eNew funding can dilute shareholders\u003c\/li\u003e\n\u003cli\u003eWeak markets can pressure liquidity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCell therapy manufacturing and scale-up risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCell therapy manufacturing is a real scale-up risk because each dose can be patient-specific, so even small errors in identity, potency, or sterility can stop a batch. For Lisata Therapeutics, Inc., any delay in process transfer, quality control, or cold-chain supply can push trials back and lift commercialization costs. That makes timelines less predictable and raises execution risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eComplex, patient-specific production\u003c\/li\u003e\n\u003cli\u003eQuality and sterility bottlenecks\u003c\/li\u003e\n\u003cli\u003eSupply-chain delays can slow trials\u003c\/li\u003e\n\u003cli\u003eScale-up failures can raise launch risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLisata Faces High Clinical Risk as One Asset and Funding Pressure Loom\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLisata Therapeutics, Inc. still carries high clinical risk because certepetide remains in Phase II\/IIb, and one missed endpoint could erase most near-term value. With only one lead asset, any delay can hit the whole pipeline and force more funding. Competition and trial scale-up also raise the odds of dilution and timeline slips.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead asset risk\u003c\/td\u003e\n\u003ctd\u003e1 lead asset; Phase II\/IIb\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReview delay\u003c\/td\u003e\n\u003ctd\u003e6-12 months+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding pressure\u003c\/td\u003e\n\u003ctd\u003eNo approved product cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234613305609,"sku":"lsta-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lsta-swot-analysis.webp?v=1785724261","url":"https:\/\/dcfanalyst.com\/products\/lsta-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}